Stay updated on Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial

Sign up to get notified when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page

  1. Check
    2 days ago
    No Change Detected
  2. Check
    10 days ago
    Change Detected
    Summary
    Footer revision tag updated from v3.6.2 to v3.6.3, signaling a minor platform update. No study content or user-facing information was changed.
    Difference
    0.1%
    Check dated 2026-07-05T05:12:14.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    Revision tag updated from v3.6.0 to v3.6.2 on the page. This indicates a new site revision/version applied to the record history page.
    Difference
    0.1%
    Check dated 2026-06-28T02:04:46.000Z thumbnail image
  4. Check
    31 days ago
    Change Detected
    Summary
    Recruitment status updated to 'No longer looking for participants' and the study record version updated to v3.6.0, replacing the previous v3.5.5.
    Difference
    0.2%
    Check dated 2026-06-13T17:42:58.000Z thumbnail image
  5. Check
    38 days ago
    Change Detected
    Summary
    The page now shows a new site revision label (Revision: v3.5.5) replacing the previous one, signaling an internal update to the ClinicalTrials.gov interface without changing the study history data.
    Difference
    0.1%
    Check dated 2026-06-06T14:41:35.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    A new revision entry v3.5.4 is added to the study's record history, replacing the previous v3.5.3. This reflects an updated version label for the page rather than substantive changes to the study data.
    Difference
    0.1%
    Check dated 2026-05-15T23:53:37.000Z thumbnail image
  7. Check
    67 days ago
    Change Detected
    Summary
    Version 57 was added on 2026-05-01, and the record now shows a QC status of Has Not Concluded. The history presents expanded content areas such as Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, and related document sections.
    Difference
    1.0%
    Check dated 2026-05-08T23:10:20.000Z thumbnail image

Stay in the know with updates to Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Phase 2 NSCLC Platform Study Post-Osimertinib Clinical Trial page.